แบบฟอร์มกำกับและติดตามการใช้ Molnupiravir สำหรับผู้

molnupiravir dose  Breastfeeding is not recommended during treatment and for 4 days after the last dose of molnupiravir A lactating individual may consider interrupting Medication Instruction- Oral Antiviral Drug for COVID-19 用藥指導-COVID-19治療口服抗病毒藥品Molnupiravir · Capsule-based dosage · Take the medicine

We have shown that a dose of 800mg bd of molnupiravir is safe and well-tolerated in participants with SARS CoV-2 infection; the plasma dose of molnupiravir or placebo, and were not hospitalized before the first dose Every effort was made to ascertain survival and

consistent and reliable method of contraception for 3 months after the male has completed the last dose of this medication 2) Men of reproductive age • If dose of molnupiravir Recommend interrupting breastfeeding or pumping and discarding breast milk during treatment and for four days after